Patents by Inventor Jessica Frie
Jessica Frie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10160751Abstract: The present invention provides compounds of Formula (I); and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: February 8, 2016Date of Patent: December 25, 2018Inventors: Alexander Pasternak, Jessica Frie, Shuzhi Dong, Takao Suzuki, Shouning Xu
-
Patent number: 9951052Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: October 27, 2014Date of Patent: April 24, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Haifeng Tang, Jessica Frie, Ronald Dale Ferguson, Zhiqiang Guo, Zhi-Cai Shi, Brian Cato, Qinghong Fu
-
Publication number: 20180016263Abstract: The present invention provides compounds of Formula (I); and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: February 8, 2016Publication date: January 18, 2018Inventors: Alexander Pasternak, Jessica Frie, Shuzhi Dong, Takao Suzuki, Shouning Xu
-
Patent number: 9850245Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: October 26, 2015Date of Patent: December 26, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Fa-Xiang Ding, Shuzhi Dong, Jinlong Jiang, Haifeng Tang, Xin Gu, Reynalda K. DeJesus, Jessica Frie, Qinghong Fu, Takao Suzuki, Zhifa Pu
-
Publication number: 20170275298Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: October 26, 2015Publication date: September 28, 2017Inventors: Alexander Pasternak, Shuzhi Dong, Xin Gu, Jinlong Jiang, Zhi-Cai Shi, Shawn P. Walsh, Zhicai Wu, Yang Yu, Ronald Ferguson, II, Zhiqiang Guo, Jessica Frie, Takao Suzuki, Timothy A. Blizzard, Qinghong Fu, Kelsey F. Vangelder
-
Publication number: 20170275283Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: October 26, 2015Publication date: September 28, 2017Inventors: Alexander Pasternak, Fa-Xiang Ding, Shuzhi Dong, Jinlong Jiang, Haifeng Tang, Xin Gu, Reynalda K. DeJesus, Jessica Frie, Qinghong Fu, Takao Suzuki, Zhifa Pu
-
Patent number: 9751881Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: July 28, 2014Date of Patent: September 5, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Haifeng Tang, Barbara Pio, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Ronald Dale Ferguson, II, Zack Zhiqiang Guo, Harry Chobanian, Jessica Frie, Yan Guo, Zhicai Wu, Yang Yu, Ming Wang
-
Patent number: 9527830Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: GrantFiled: September 10, 2012Date of Patent: December 27, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Shawn Walsh, Alexander Pasternak, Brian Cato, Paul E. Finke, Jessica Frie, Qinghong Fu, Dooseop Kim, Barbara Pio, Aurash Shahripour, Zhi-Cai Shi, Haifeng Tang
-
Publication number: 20160257670Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: October 27, 2014Publication date: September 8, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Haifeng Tang, Jessica Frie, Ronald Dale Ferguson, Zhiqiang Guo, Zhi-Cai Shi, Brian Cato, Qinghong Fu
-
Publication number: 20160207922Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: July 28, 2014Publication date: July 21, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Haifeng Tang, Barbara Pio, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Ronald Dale Ferguson, II, Zack Zhiqiang Guo, Harry Chobanian, Jessica Frie, Yan Guo, Zhicai Wu, Yang Yu, Ming Wang
-
Patent number: 9206198Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: GrantFiled: December 15, 2014Date of Patent: December 8, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Fa-Xiang Ding, Shuzhi Dong, Jessica Frie, Xin Gu, Jinlong Jiang, Alexander Pasternak, Haifeng Tang, Zhicai Wu, Yang Yu, Takao Suzuki
-
Publication number: 20150099729Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: ApplicationFiled: December 15, 2014Publication date: April 9, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Fa-Xiang Ding, Shuzhi Dong, Jessica Frie, Xin Gu, Jinlong Jiang, Alexander Pasternak, Haifeng Tang, Zhicai Wu, Yang Yu, Takao Suzuki
-
Patent number: 8952166Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: GrantFiled: July 25, 2013Date of Patent: February 10, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Fa-Xiang Ding, Shuzhi Dong, Jessica Frie, Xin Gu, Jinlong Jiang, Alexander Pasternak, Haifeng Tang, Zhicai Wu, Yang Yu, Takao Suzuki
-
Publication number: 20140235628Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: ApplicationFiled: September 10, 2012Publication date: August 21, 2014Inventors: Shawn Walsh, Alexander Pasternak, Brian Cato, Paul E. Finke, Jessica Frie, Qinghong Fu, Dooseop Kim, Barbara Pio, Aurash Shahripour, Zhi-Cai Shi, Haifeng Tang
-
Publication number: 20140031349Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: ApplicationFiled: July 25, 2013Publication date: January 30, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Fa-Xiang Ding, Shuzhi Dong, Jessica Frie, Xin Gu, Jinlong Jiang, Alexander Pasternak, Haifeng Tang, Zhicai Wu, Yang Yu, Takao Suzuki
-
Publication number: 20070299101Abstract: The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.Type: ApplicationFiled: October 31, 2005Publication date: December 27, 2007Inventors: Steven Colletti, Richard Beresis, Weichun Chen, James Tata, Hong Shen, Daria Marley, Qiaolin Deng, Jessica Frie, Fa-Xiang Ding
-
Publication number: 20070281969Abstract: The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: November 18, 2005Publication date: December 6, 2007Inventors: Steven Colletti, James Tata, Hong Shen, Fa-Xiang Ding, Jessica Frie, Jason Imbriglio, Weichun Chen
